Liminatus PharmaLIMN +22.63%13 EBIT per Share is $-0.39 as of Mar. 2026. GuruFocus rates LIMN with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 1,174 Biotechnology companies, Liminatus Pharma ranks worse than 77.09% on this metric.
Liminatus Pharma's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.03.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.39.
During the past 3 years, the average EBIT per Share Growth Rate was -6.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Liminatus Pharma's EBIT per Share or its related term are showing as below:
LIMN'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -6.3 Med: -6.3 Max: -6.3
Current: -6.3
During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Liminatus Pharma was -6.30% per year. The lowest was -6.30% per year. And the median was -6.30% per year.
LIMN's 3-Year EBIT Growth Rate is ranked worse than 77.09% of 1174
companies
in the Biotechnology industry
Industry Median: 15.4
vs LIMN: -6.30
Liminatus Pharma (NAS:LIMN) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Liminatus Pharma EBIT per Share Related Terms
Liminatus Pharma EBIT per Share Historical Data
* Premium members only.
The historical data trend for Liminatus Pharma's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.39
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liminatus Pharma (LIMN) has a EBIT per Share of $-0.39 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Liminatus Pharma and its competitors. According to the industry distribution chart, Liminatus Pharma ranks #905 out of 1174 companies in the Biotechnology industry, placing it in the top 77.1%.
Is Liminatus Pharma's EBIT per Share too high?
Liminatus Pharma's current EBIT per Share is $-0.39. Based on the distribution chart, Liminatus Pharma ranks #905 out of 1174 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Liminatus Pharma has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Liminatus Pharma's EBIT per Share compare to GNPX and PCSA?
According to the Biotechnology industry distribution chart, Liminatus Pharma ranks #905 out of 1174 companies for EBIT per Share. This places Liminatus Pharma in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,174 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Liminatus Pharma and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liminatus Pharma's current EBIT per Share is $-0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liminatus Pharma stock overvalued right now?
Liminatus Pharma (LIMN) has a current EBIT per Share of $-0.39. The current EBIT per Share is $-0.39. Liminatus Pharma's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Liminatus Pharma (LIMN), the current EBIT per Share is $-0.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
13GF Score
Get the complete analysis for LIMN
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIMN has been successfully added to your 
